6-[5-(3-chloro-4-fluoro-phenyl)-3-(2-hydroxyethyl)imidazol-4-yl]imidazo[1,2-b]pyridazine-3-carbonitrile

ID: ALA4514379

PubChem CID: 122510453

Product Number: B608158, Order Now?

Max Phase: Preclinical

Molecular Formula: C18H12ClFN6O

Molecular Weight: 382.79

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  N#Cc1cnc2ccc(-c3c(-c4ccc(F)c(Cl)c4)ncn3CCO)nn12

Standard InChI:  InChI=1S/C18H12ClFN6O/c19-13-7-11(1-2-14(13)20)17-18(25(5-6-27)10-23-17)15-3-4-16-22-9-12(8-21)26(16)24-15/h1-4,7,9-10,27H,5-6H2

Standard InChI Key:  VZZBCNXVZFAIQX-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 27 30  0  0  0  0  0  0  0  0999 V2000
   33.8224  -14.4356    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   34.5320  -14.0262    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.5292  -13.2035    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.8206  -12.7982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   33.1143  -14.0266    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.1155  -13.2056    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3350  -12.9506    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   31.8514  -13.6142    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   32.3331  -14.2791    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.2364  -14.4317    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.3231  -15.2443    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   36.1227  -15.4129    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.5302  -14.7045    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   35.9824  -14.0982    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.1509  -13.3007    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.9292  -13.0478    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   37.0980  -12.2491    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.4894  -11.7023    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.7095  -11.9599    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   35.5444  -12.7581    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.6109  -15.6463    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   34.6031  -16.4635    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   36.6570  -10.9025    0.0000 F   0  0  0  0  0  0  0  0  0  0  0  0
   32.0744  -15.0573    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   31.8207  -15.8341    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   33.8914  -16.8652    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
   37.8749  -11.9956    0.0000 Cl  0  0  0  0  0  0  0  0  0  0  0  0
  5  1  1  0
  1  2  2  0
  2  3  1  0
  3  4  2  0
  4  6  1  0
  5  6  1  0
  6  7  2  0
  7  8  1  0
  8  9  2  0
  9  5  1  0
 10 11  1  0
 11 12  1  0
 12 13  2  0
 13 14  1  0
 14 10  2  0
  2 10  1  0
 15 16  2  0
 16 17  1  0
 17 18  2  0
 18 19  1  0
 19 20  2  0
 20 15  1  0
 14 15  1  0
 11 21  1  0
 21 22  1  0
 18 23  1  0
 24 25  3  0
  9 24  1  0
 22 26  1  0
 17 27  1  0
M  END

Alternative Forms

1. Parent:

   

   ALA4514379

   BMS-986260

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 382.79

Molecular Weight (Monoisotopic): 382.0745

AlogP: 2.92

#Rotatable Bonds: 4

Polar Surface Area: 92.03

Molecular Species: NEUTRAL

HBA: 7

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 7

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 4.41

CX LogP: 2.58

CX LogD: 2.58

Aromatic Rings: 4

Heavy Atoms: 27

QED Weighted: 0.59

Np Likeness Score: -1.98

References

1. Velaparthi U, Darne CP, Warrier J, Liu P, Rahaman H, Augustine-Rauch K, Parrish K, Yang Z, Swanson J, Brown J, Dhar G, Anandam A, Holenarsipur VK, Palanisamy K, Wautlet BS, Fereshteh MP, Lippy J, Tebben AJ, Sheriff S, Ruzanov M, Yan C, Gupta A, Gupta AK, Vetrichelvan M, Mathur A, Gelman M, Singh R, Kinsella T, Murtaza A, Fargnoli J, Vite G, Borzilleri RM..  (2020)  Discovery of BMS-986260, a Potent, Selective, and Orally Bioavailable TGFβR1 Inhibitor as an Immuno-oncology Agent.,  11  (2): [PMID:32071685] [10.1021/acsmedchemlett.9b00552]

2. Zhang Y, Parrish KE, Tortolani DR, Poss MA, Huang A, Wan H, Purandare AV, Donnell AF, Kempson J, Hou X, Pawluczyk J, Yip S, Luk E, Raghavan N, Swanson J, Smalley J, Murtaza A, Yang Z, Augustine-Rauch K, Lombardo LJ, Borzilleri R..  (2021)  Long-Acting Tumor-Activated Prodrug of a TGFβR Inhibitor.,  64  (21): [PMID:34704759] [10.1021/acs.jmedchem.0c02043]

Source

Source(1):

• Scientific Literature